2026 Annual Report Transforming Clinical Evidence into Commercial Growth I 2026 Transforming Clinical Evidence into Commercial Growth Meeting one of oncology’s greatest unmet needs requires more than innovation—it demands clinical evidence, regulatory progress and commercial execution....
Annual Report (Typeset)
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from OncoSil Medical
- Peer-Reviewed Study Reports 100% Disease Control
- Change of Director's Interest Notice
- Notification of cessation of securities - OSL
- Updated OSPREY Overall Survival Data Presented at EAMN
- Notice of Annual General Meeting/Proxy Form
Later from OncoSil Medical
- Quarterly Activities/Appendix 4C Cash Flow Report
- Regulatory Application Filed for Australian Manufacturing
